Oppenheimer analyst Michael Wiederhorn reiterated an Outperform rating and $265.00 price target on Amedisys (NASDAQ: AMED) following a meeting with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE